Oligonucleotides as antivirals: Dream or realistic perspective?

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 307-316

  Van Aerschot, Arthur ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antisense oligonucleotides; Antiviral activity; HCMV; HIV 1; HSV 1

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CIDOFOVIR; DEOXYURIDINE PHOSPHATE; FOMIVIRSEN; GENE EXPRESSION MODULATOR 132; IMMUNOLIPOSOME; METHYLPHOSPHONIC ACID; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE METHYLPHOSPHONATE; OLIGODEOXYNUCLEOTIDE PHOSPHODIESTER; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RIBONUCLEASE H; TRECOVIRSEN; UNCLASSIFIED DRUG; WO 9733992; ZINTEVIR;

ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VIRUS GENOME;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; HIV-1; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; SIMPLEXVIRUS; VIRUS DISEASES;

HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33747101631     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.03.003     Document Type: Short Survey

References (70)

1. Alter J., Lou F., Rabinowitz A., Yin H.F., Rosenfeld J., Wilton S.D., Partridge T.A., and Lu Q.L. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12 (2006) 175-177
2. Anazodo M.I., Wainberg M.A., Friesen A.D., and Wright J.A. Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome. J. Virol. 69 (1995) 1794-1801
3. Anderson K.P., Fox M.C., Brown-Driver V., Martin M.J., and Azad R.F. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40 (1996) 2004-2011
4. Azad R.F., Driver V.B., Tanaka K., Crooke R.M., and Anderson K.P. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37 (1993) 1945-1954
5. Boulme F., Freund F., Moreau S., Nielsen P.E., Gryaznov S., Toulme J.J., and Litvak S. Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucleic Acids Res. 26 (1998) 5492-5500
6. Buck H.M., Koole L.H., van Genderen M.H.P., Smit L., Geelen J.L.M.C., Jurriaans S., and Goudsmit J. Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity. Science 248 (1990) 208-212
7. Buck H.M. The chemical and biochemical properties of methylphosphotriester DNA. Nucleosides Nucleotides Nucleic 23 (2004) 1833-1847
8. Chaubey B., Tripathi S., Ganguly S., Harris D., Casale R.A., and Pandey V.N. A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties. Virology 331 (2005) 418-428
9. Cherepanov P., Esté J.A., Rando R.F., Ojwang J.O., Reekmans G., Steinfeld R., David G., De Clercq E., and Debyser Z. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol. Pharmacol. 52 (1997) 771-780
10. Colbère-Garapin F., Blondel B., Saulnier A., Pelletier I., and Labadie K. Silencing viruses by RNA interference. Microbes Infect. 7 (2005) 767-775
11. Crooke S.T. Molecular mechanisms of action of antisense drugs. BBA-Gene Struct. Expr. 1489 (1999) 31-43
12. De Clercq E. Fomivirsen: a viewpoint. Drugs 57 (1999) 381
13. Dolnick B.J. Naturally occurring antisense RNA. Pharmacol. Therapeut. 75 (1997) 179-184
14. Field A.K. Viral targets for antisense oligonucleotides: a mini review. Antiviral Res. 37 (1998) 67-81
15. Herdewijn P. Conformationally restricted carbohydrate-modified nucleic acids and antisense technology. BBA-Gene Struct. Expr. 1489 (1999) 167-179
16. Holden K.L., Stein D.A., Pierson T.C., Ahmed A.A., Clyde K., Iversen P.L., and Harris E. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3′ stem-loop structure. Virology 344 (2006) 439-452
17. 35. Virology 334 (2005) 214-223
18. Jiang Z., Kandimalla E.R., Zhao Q., Shen L.X., DeLuca A., Normano N., Ruskowski M., and Agrawal S. Pseudo-cyclic oligonucleotides: in vitro and in vivo properties. Bioorg. Med. Chem. 7 (1999) 2727-2735
19. Lys in the virions and inhibits HIV-1 replication. Virology 303 (2002) 297-308
20. Kaushik N., Basu A., and Pandey V.N. Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog. Antiviral Res. 56 (2002) 13-27
21. Kean J.M., Kipp S.A., Miller P.S., Kulka M., and Aurelian L. Inhibition of herpes simplex virus replication by antisense oligo-2′-O-methylribonucleoside methylphosphonates. Biochemistry 34 (1995) 14617-14620
22. Koppelhus U., and Nielsen P.E. Cellular delivery of peptide nucleic acid (PNA). Adv. Drug Deliv. Rev. 55 (2003) 267-280
23. Koshkin A.A., Singh S.K., Nielsen P., Rajwanshi V.K., Kumar R., Meldgaard M., Olsen C.E., and Wengel J. LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation and unprecendented nucleic acid recognition. Tetrahedron 54 (1998) 3607-3630
24. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., and Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
25. Kulka M., Smith C.C., Aurelian L., Fishelevich R., Meade K., Miller P., and Ts'o P.O.P. Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 6868-6872
26. Kulka M., Wachsman M., Miura S., Fishelevich R., Miller P., Ts'o P.O.P., and Aurelian L. Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes-simplex virus type-1 immediate early messenger RNA-4 and messenger RNA-5. Antiviral Res. 20 (1993) 115-130
27. Kurreck J., Wyszko E., Gillen C., and Erdmann V.A. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30 (2002) 1911-1918
28. Lund O.S., Nielsen J.O., and Hansen J.S. Inhibition of HIV-1 in vitro by C-5 propyne phosphorothioate antisense to rev. Antiviral Res. 28 (1995) 81-91
29. Manoharan M. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. BBA-Gene Struct. Expr. 1489 (1999) 117-130
30. Matsukura M., Shinozuka K., Zon G., Mitsuya H., Reitz M., Cohen J.S., and Broder S. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7706-7710
31. Matsukura M., Zon G., Shinozuka K., Robert-Guroff M., Shimada T., Stein C.A., Mitsuya H., Wong-Staal F., Cohen J.S., and Broder S. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 4244-4248
32. Miller P.S., Agris C.H., Aurelian L., Blake K.R., Murakami A., Reddy M.P., Spitz S.A., and Ts'o P.O.P. Control of ribonucleic acid function by oligonucleoside methylphosphonates. Biochemie 67 (1985) 769-776
33. Moody H.M., Quaedflieg P.J.L.M., Koole L.H., van Genderen M.H.P., Buck H.M., Smit L., Jurriaans S., and Goudsmit J. Inhibition of HIV-1 infectivity by phosphate-methylated DNA-retraction. Science 250 (1990) 125-126
34. Mulamba G.B., Hu A., Azad R.F., Anderson K.P., and Coen D.M. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 42 (1998) 971-973
35. Nielsen P.E. PNA technology. Mol. Biotechnol. 26 (2004) 233-248
36. Obika S., Nanbu D., Hari Y., Andoh J.-I., Morio K.-I., Doi T., and Imanishi T. Stability and structural features of the duplexes containing nucleoside analogues with fixed N-type conformation, 2′-O,4′-C-methyleneribonucleosides. Tetrahedron Lett. 39 (1998) 5401-5404
37. Ojwang J.O., Buckheit R., Pommier Y., Mazumder A., De Vreese K., Esté J.A., Reymen D., Pallansch L., Lackman-Smith C., Wallace T., De Clercq E., McGrath M., and Rando R.F. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39 (1995) 2426-2435
38. Pari G.S., Field A.K., and Smith J.A. Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob. Agents Chemother. 39 (1995) 1157-1161
39. Paterson B.M., Roberts B.E., and Kuff E.L. Structural gene identification and mapping by DNA·mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 4370-4374
40. Peyman A., Helsber M., Kretzschmar G., Mag M., Grabley S., and Uhlmann E. Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol. Chem. 376 (1995) 195-198
41. Peyman A., Helsberg M., Kretzschmar G., Mag M., Ryte A., and Uhlmann E. Nuclease stability as dominant factor in the antiviral activity of oligonucleotides directed against HSV-1 IE110. Antiviral Res. 33 (1997) 135-139
42. Poddevin B., Meguenni S., Elias I., Vasseur M., and Blumenfeld M. Improved anti-herpes simplex virus type 1 activity of a phosphodiester antisense oligonucleotide containing a 3′-terminal hairpin-like structure. Antisense Res. Dev. 4 (1994) 147-154
43. Pooga M., Land T., Bartfai T., and Langel U. PNA oligomers as tools for specific modulation of gene expression. Biomol. Eng. 17 (2001) 183-192
44. Praseuth D., Guieysse A.L., and Hélène C. Triple helix formation and the antigene strategy for sequence-specific control of gene expression. BBA-Gene Struct. Expr. 1489 (1999) 181-206
45. Rando R.F., Ojwang J., Elbaggari A., Reyes G.R., Tinder R., McGrath M.S., and Hogan M.E. Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads. J. Biol. Chem. 270 (1995) 1754-1760
46. Scholz M., Doerr H.W., and Cinatl J. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option?. Antiviral Res. 49 (2001) 129-145
47. Selvam M.P., Buck S.M., Blay R.A., Mayner R.E., Mied P.A., and Epstein J.S. Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiviral Res. 33 (1996) 11-20
48. Simons R.W. Naturally occurring antisense RNA control-a brief review. Gene 72 (1988) 35-44
49. Smith C.C., Aurelian L., Reddy M.P., Miller P.S., and Ts'o P.O.P. Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 2787-2791
50. Smith J.A., and Pari G.S. Expression of human cytomegalovirus UL36 and UL37 genes is required for viral DNA replication. J. Virol. 69 (1995) 1925-1931
51. Stein C.A., Matsukura M., Subasinghe C., Broder S., and Cohen J.S. Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. AIDS Res. Hum. Retroviruses 5 (1989) 639-646
52. Stein C.A., Neckers L.M., Nair B.C., Mumbauer S., Hoke G., and Pal R. Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. J. Acquir. Immune Defic. Syndr. 4 (1991) 686-693
53. Stein C.A., Cleary A.M., Yabukov L., and Lederman S. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. Antisense Res. Dev. 3 (1993) 19-31
54. Stephenson M.L., and Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 285-288
55. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. BBA-Gene Struct. Expr. 1489 (1999) 141-158
56. Tauchi T., Sumi M., Nakajima A., Sashida G., Shimamoto T., and Ohyashiki K. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin. Cancer Res. 9 (2003) 4267-4273
57. Tripathi S., Chaubey B., Ganguly S., Harris D., Casale R.A., and Pandey V.N. Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucleic Acids Res. 33 (2005) 4345-4356
58. Uhlmann E., and Peyman A. Antisense oligonucleotides-a new therapeutic principle. Chem. Rev. 90 (1990) 543-584
59. Vaillant A., Lu H., Liu S., Lackman-Smith C., Ptak R., Juteau J.-M., and Jiang S. Phosphorothioate oligonucleotides inhibit HIV-1 fusion by blocking gp41 core formation. Antimicrob. Agents Chemother. 50 (2006) 1393-1401
60. van Deventer S.J.H., Tami J.A., and Wedel M.K. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 53 (2004) 1646-1651
61. Verbeure B., Lescrinier E., Wang J., and Herdewijn P. RNase H mediated cleavage of RNA by cyclohexene nucleic acid (CeNA). Nucleic Acids Res. 29 (2001) 4941-4947
62. Verheijen J.C., van der Marel G.A., van Boom J.H., Bayly S.F., Player M.R., and Torrence P.F. 2′,5′-Oligoadenylate-peptide nucleic acids (2-5A-PNAs) activate RNase L. Bioorg. Med. Chem. 7 (1999) 449-455
63. Wagner R.W., Matteucci M.D., Lewis J.G., Gutierrez A.J., Moulds C., and Froehler B.C. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260 (1993) 1510-1513
64. Wilds C.J., and Damha M.J. 2′-Deoxy-2′-fluoro-β-d-arabinonucleosides and oligonucleotides (2′F-ANA): synthesis and physicochemical studies. Nucleic Acids Res. 28 (2000) 3625-3635
65. Wyatt J.R., Vickers T.A., Roberson J.L., Buckheit Jr. R.W., Klimkait T., De Baets E., Davis P.W., Rayner B., Imbach J.L., and Ecker D.J. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 1356-1360
66. Yamaguchi K., Papp B., Zhang D., Ali A.N., Agrawal S., and Byrn R.A. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 13 (1997) 545-554
67. Zamecnik P.C., and Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 280-284
68. Zhang Z., Smith J.A., Smyth A.P., Tang J.Y., Eisenberg W., and Pari G.S. Inhibition of human cytomegalovirus DNA replication with a phosphorothioate cholesteryl-modified oligonucleotide is mediated br by rapid cellular association and virus-facilitated nuclear localization. Antiviral Chem. Chemother. 8 (1997) 255-264
69. Zelphati O., Imbach J.L., Signoret N., Zon G., Rayner B., and Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. 22 (1994) 4307-4314
70. Zhou L., Civitello E.R., Gupta N., Silverman R.H., Molinaro R.J., Anderson D.E., and Torrence P.F. Endowing RNase H-inactive antisense with catalytic activity: 2-5A-morphants. Bioconjugate Chem. 16 (2005) 383-390